SOURCE: Generex Biotechnology

April 20, 2007 09:45 ET

Generex Biotechnology Granted Patents in Canada and Mexico

Company Expands North American Drug Delivery Platform Patent Portfolio

TORONTO -- (MARKET WIRE) -- April 20, 2007 -- Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has expanded its patent portfolio with newly issued patents in Canada and Mexico issued by the Canadian Intellectual Property Office and the Mexican Institute of Intellectual Property, respectively.

The Canadian patent titled "Pulmonary Drug Delivery" contains claims to an aerosol pharmaceutical formulation, metered dose dispenser, and use thereof. The patent discloses an improved delivery system for the administration of large molecule pharmaceuticals which can be administered by means of an aerosol into the mouth for buccal or pulmonary application.

The Mexican patent titled "Micellar Pharmaceutical Compositions for Buccal and Pulmonary Application" is an extant United States Patent held by the Company containing claims to pharmaceutical compositions comprising a macromolecular pharmaceutical agent in mixed micellar form. The patent also discloses methods for making and using the pharmaceutical compositions.

"We welcome the expansion of our intellectual property protection in North America as the Company moves forward on its clinical and regulatory path in the major markets," said Rose C. Perri, the Company's Chief Operating Officer. "The addition of a new Mexican patent is significant as this market will prove valuable for our flagship product Generex Oral-lyn ™ and future indications utilizing the RapidMist™ platform."

The Company currently holds an aggregate of 84 patents worldwide (20 of which are United States Patents) and has an aggregate of 58 patent applications pending in various jurisdictions.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact Information

  • For more information, please contact:

    For Generex:
    Shayne Gilliatt
    Generex
    800-391-6755
    416-364-2551

    Andrew Hellman
    CEOcast, Inc.
    212-732-4300